In the clinical setting, Ki67 serves as a prognostic marker for ovarian cancer, reflecting cellular proliferation rates, while PAX8 identifies the gynecological origin of the malignancy, correlating with patient outcomes. This evidence concerns the gene MKI67 and ovarian carcinoma.